Clinical Trials Browser

Has results × Neoplasms × Cetuximab × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00321100 2022-01-12

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Phase 2 Terminated

23 enrolled 8 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT01332266 2022-01-03

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Completed

95 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT00957853 2020-03-19

Preoperative Treatment With Cetuximab and/or IMC-A12

Phase 2 Completed

16 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms

NCT00468169 2019-10-09

EPIC

Phase 2 Completed

110 enrolled 14 charts

Head & Neck

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1/2 Terminated

15 enrolled 11 charts

Tumor-Agnostic

Neoplasms

NCT00870870 2018-06-01

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Phase 2 Completed

64 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00226239 2017-07-11

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Phase 2 Completed

39 enrolled 10 charts

Tumor-Agnostic

Neoplasms

NCT00591149 2017-06-14

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Phase 2 Terminated

16 enrolled 5 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT00703976 2017-04-04

Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

Phase 2 Completed

80 enrolled 7 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms

NCT00350025 2017-03-31

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Phase 2 Completed

41 enrolled 11 charts

Genitourinary

Neoplasm Metastasis, Neoplasms, Urologic Neoplasms

NCT00110357 2015-12-24

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Phase 1 Completed

48 enrolled 22 charts

Tumor-Agnostic

Neoplasms

NCT00439517 2014-06-27

FUTURE

Phase 2 Completed

302 enrolled 18 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00463788 2014-02-13

BALI-1

Phase 2 Completed

181 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00083720 2011-05-25

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Phase 2 Completed

87 enrolled 14 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

Clinical Trials

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Preoperative Treatment With Cetuximab and/or IMC-A12

EPIC

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

FUTURE

BALI-1

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy